{
    "nct_id": "NCT05592678",
    "title": "Novel Methods for Clinical Trials in Dementia and Cognitive Decline",
    "status": "RECRUITING",
    "last_update_time": "2025-04-02",
    "description_brief": "The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are:\n\n* Can an intervention's outcome be better assessed by a latent variable (\"\u03b4\") integrating cognitive performance with functional status?\n* Can latent biomarkers of \u03b4 guide the selection of an intervention that will modulate dementia severity?\n* Can a latent variable, derived from information collected remotely from caregivers, preselect subjects most likely to respond to the intervention?\n* Is the effect of the intervention in fact medicated by changes in the targeted biomarker?\n\nIn this case, the biomarker will be a latent variable derived from several proteins measured in blood (i.e., so-called \"adipokines\"). The intervention will be donepezil, a medication approved for the treatment of Alzheimer's Disease, but only recently associated with adipokine changes.\n\nParticipants with cognitive impairment and their caregivers will be interviewed by telephone and those newly prescribed donepezil by their provider for cognitive impairment will be recruited and enrolled. On the basis of the caregiver's report, the cognitively impaired subjects will be assigned to two groups based on a prediction of their response to donepezil. Researchers will compare those groups to see if dementia severity, as measured by \u03b4, improves in predicted responders, and whether the change in the d-score is mediated by changes in adipokines.",
    "description_detailed": "Title: \"Novel Methods for Clinical rials in Dementia and Cognitive Decline\"\n\nStudy Description: This is a double-blind assignment clinical study to test novel approaches to clinical trial methods. 1) The study team will pre-select cases most likely to benefit from adipokine modulation by a telephone assessment. 2) The study team will pre-select subjects with clinical and preclinical dementia most likely to respond to therapy. 3) The study team will test the drug donepezil's effect on dementia severity, in predicted responders and non-responders, as measured by a latent dementia phenotype \"\u03b4' and 4) test a latent Adipokines biomarker construct as a mediator of their association in the predicted responders.\n\nObjectives:\n\nPrimary Objective: To assess donepezil's effect on dementia severity as measured by \u03b4 in LOI subgroups and across LOI subgroups.\n\nSecondary Objective: To test Adipokines as a mediator of donepezil's effect on dTEL.\n\nTertiary/Exploratory: To test whether donepezil reverses dementia in cases preselected to by \"LOI\" analysis.",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "donepezil"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is donepezil, a centrally acting reversible acetylcholinesterase inhibitor used to improve cognition and behavior in Alzheimer disease (symptomatic, not proven to alter disease progression). \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Act: Key trial details extracted from the description \u2014 intervention: donepezil (patients newly prescribed by their provider); biomarker: a latent 'Adipokines' construct derived from multiple blood proteins; outcome construct: latent dementia-severity measure '\u03b4' (combining cognition + function); caregiver-remote data used for preselection. The literature shows donepezil has been associated with changes in adipokine levels (e.g., alterations in serum leptin and adiponectin during treatment). \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Act (classification): Given donepezil's known mechanism and clinical use as a symptomatic acetylcholinesterase inhibitor (a small-molecule cognitive enhancer rather than an agent targeting core AD pathology such as amyloid or tau), the trial best fits the 'cognitive enhancer' category. The trial is testing whether donepezil's clinical effect (on the \u03b4 score) is mediated by adipokine changes and whether adipokine-based latent biomarkers can predict response \u2014 but that does not change the intervention's primary pharmacologic class or intent. \ue200cite\ue202turn0search4\ue202turn0search7\ue201",
        "Reflect: Supporting background \u2014 adipokines are biologically linked to dementia risk and have been associated with dementia severity/\u03b4 in prior work, which is why they are plausible mediators/predictors in this study. The cited studies demonstrate (a) adipokines' relation to dementia and \u03b4, and (b) observed adipokine changes with donepezil treatment, supporting the trial's proposed mediation/prediction analyses. These sources were used to verify the drug's mechanism and the adipokine rationale. \ue200cite\ue202turn0search7\ue202turn0search6\ue202turn0search1\ue201",
        "Web-search results used (key sources): 1) Donepezil mechanism and symptomatic use (review/summary). \ue200cite\ue202turn0search4\ue202turn0search5\ue201 2) Studies reporting donepezil-associated changes in serum adipokines (leptin/adiponectin). \ue200cite\ue202turn0search1\ue202turn0search2\ue201 3) Work linking adipokines to dementia severity and specifically to the latent \u03b4 construct. \ue200cite\ue202turn0search7\ue202turn0search3\ue201 4) Reviews on adipokines as mediators between peripheral metabolism and brain/dementia. \ue200cite\ue202turn0search6\ue202turn0search9\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The intervention is donepezil, a centrally acting, reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine and enhances cholinergic neurotransmission \u2014 a canonical neurotransmitter-modulating cognitive enhancer rather than an anti-amyloid or anti-tau disease-modifying agent. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Act: Extracted trial details \u2014 drug: donepezil (AChE inhibitor); study aim: test cognitive effect (\u03b4 score) and adipokine-based biomarkers as mediators/predictors. Because donepezil\u2019s primary pharmacologic action is modulation of cholinergic neurotransmission, the best CADRO match is D) Neurotransmitter Receptors (neurotransmitter-system modulation). The adipokine biomarker focus does not change the drug\u2019s mechanism. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Reflect: Verification \u2014 donepezil\u2019s mechanism as an acetylcholinesterase inhibitor and symptomatic cognitive enhancer is well established, and there is literature showing donepezil-associated changes in adipokines as well as adipokines\u2019 association with dementia severity (\u03b4), which explains the trial\u2019s biomarker rationale but does not change the pharmacologic CADRO classification. Therefore D) Neurotransmitter Receptors is the most specific, appropriate CADRO category. \ue200cite\ue202turn0search2\ue202turn0search1\ue202turn0search5\ue201",
        "Web search results used (key sources): 1) Donepezil mechanism and pharmacology (StatPearls review). \ue200cite\ue202turn0search2\ue201 2) Donepezil-associated changes in serum adipokines (leptin/adiponectin) \u2014 open-label study. \ue200cite\ue202turn0search1\ue201 3) Adipokines predict dementia severity (\u03b4) \u2014 TARCC/ADNI replication study. \ue200cite\ue202turn0search5\ue201 4) Large epidemiologic study linking adipokines (leptin/resistin) to dementia risk. \ue200cite\ue202turn0search4\ue201 5) Reviews on adipokines, inflammation and metabolism in dementia. \ue200cite\ue202turn0search6\ue202turn0search8\ue201"
    ]
}